Role of cytoreductive nephrectomy in renal cell carcinoma

Future Oncology

Volumn 5, Issue 6, 2009, Pages 859-869

  Chiong, Edmund ^a,b   Wood, Christopher G ^c   Margulis, Vitaly ^d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cytoreductive nephrectomy; Immunotherapy; Laparoscopy; Renal cell carcinoma; Targeted molecular therapy

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; VASCULOTROPIN;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPY; LOW DRUG DOSE; METASTASIS POTENTIAL; MINIMALLY INVASIVE SURGERY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SURGICAL APPROACH; SURVIVAL TIME;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEPHRECTOMY;

EID: 70349196784     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.52     Document Type: Review

References (69)

1. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
2. Wagner JR, Walther MM, Linehan WM et al.: Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J. Urol. 162, 43-45 (1999).
3. Rackley R, Novick A, Klein E et al.: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol. 152, 1399-1403 (1994).
4. Escudier B, Eisen T, Stadler WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
5. Motzer RJ, Hutson TE, Tomczak P et al.: Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
6. Hudes G, Carducci M, Tomczak P et al.: Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
7. Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J: Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol. 154, 32-34 (1995).
8. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R: Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic rental-cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001).
9. Flanigan RG, Salmon SE, Blumenstein BA et al.: Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
10. Flanigan RC, Mickisch G, Sylyester R et al.: Cytereductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
11. Zini L, Capitanio U, Perrotte P. et al.: Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 73, 342-346 (2009).
12. Vieweg J, Su Z, Dahm, P, Kusmartsev S: Reversal of tumor-mediated immunosuppression. Clin. Cancer Res. 13, 727s-732s (2007).
13. Walther MM, Alexander RB, Weiss GH et al.: Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 42, 250-257; discussion 257-258 (1993).
14. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol. 158, 1675-1678 (1997).
15. Tanguay S, Swanson DA, Putnam JB Jr: Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery. J. Urol. 156, 1586-1589 (1996).
16. Kim B, Louie AC: Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch. Surg. 127, 1343-1349 (1992).
17. Sella A, Swanson DA, Ro JY et al.: Surgery following response to interferon-α-based therapy for residual renal cell carcinoma. J. Urol. 149, 19-21; discussion 21-22 (1993).
18. Sherry RM, Pass HI, Rosenberg SA, Yang JC: Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 69, 1850-1855 (1992).
19. Krishnamurthi V, Novick AC, Bukowski RM. Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51, 933-937 (1998).
20. Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC: The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur. Urol. 42, 570-574; discussion 575-576 (2002).
21. Bex A, Kerst M, Mallo H et al.: Interferon α 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: 2 consecutive study. Eur. Urol. 49, 76-81 (2006).
22. Howdieshell TR, Callaway D, Webb WL et al.: Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J. Surg. Res. 96, 173-182 (2001).
23. Roman CD, Choy H, Nanney L et al.: Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J. Surg. Res. 105, 43-47 (2002).
24. Kesmodel SB, Ellis LM, Lin E et al.: Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab f6r colorectal cancer liver metastases. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January (2007) (Abstract 234).
25. Margulis V, Matin SF, Tannir N et al.: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180, 94-98 (2008).
26. Jonasch E: Presurgical therapy in metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 7, 73-78 (2007).
27. Wood CG: Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res. 13, 697s-702s (2007).
28. Han KR, Pantuck Aj, Bui MH et al.: Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61, 314-319 (2003).
29. Choueiri TK, Rini B, Garcia JA et al.: Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann. Oncol. 18, 249-255 (2007).
30. Leibovich BC, Cheville JC, Lohse CM et al.: A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J. Urol. 174, 1759-1763; discussion 1763 (2005).
31. Motzer RJ, Bacik J, Mariani T et al.: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376-2381 (2002).
32. Motzer RJ, Mazumdar M, Bacik J et al.: Survival and prognostic stratification of 670. patients with advanecd renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999).
33. Suppiah R, Shaheen PE, Elson P et al.: Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107, 1793-1800 (2006).
34. Vasselli JR, Yang JC, Linehan WM et al.: Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J. Urol. 166, 68-72 (2001).
35. Negrier S, Gomez F, Douillard JY et al.: Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cyrokines: a report from the Groupe Francais d'Immunotherapie. World J. Urol. 23, 161-165 (2005).
36. Mekhail TM, Abou-Jawde RM, Boumerhi G et al.: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832-841 (2005).
37. Barbastefano J, Garcia JA, Elson P et al.: Association of percentage of tumor burden removed with debulking nephrectomy and progression free survival in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy. Presented at: ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June (2009) (Abstract 219).
38. Heng DY, Xie W, Regan M et al.: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factot-targeted agents: Results from a large multicenter study. Presented at: Genitourinary Cancers Symposium. Orlando, FL, USA, 26-28 February (2009) (Abstract 284).
39. Kassouf W, Sanchez-Ortiz R, Tamboli P et al.: Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J. Urol. 178, 1896-1900 (2007).
40. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002).
41. Leibovich BC, Han KR, Bui MH et al.: Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98, 2566-2575 (2003).
42. Motzer, R.J. Figlin RA, Hutson TE et al.: Sunitinib versus interferon-α (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 1-5 June. J. Clin. Oncol. 25 (2007) (Abstract 5024).
43. Choueiri TK, Garcia JA, Elson P et al.: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110, 543-550 (2007).
44. Motzer RJ, Bukowski RM, Figlin RA et al.: Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113, 1552-1558 (2008).
45. Bui MH, Seligson D, Han KR et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
46. Atkins M, Regan M, McDermott D et al.: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714-3721 (2005).
47. Halbert RJ, Figlin RA, Atkins MB et al.: Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer 107, 2375-2383 (2006).
48. Walther MM, Lyne JC, Libutti SK, Linehan WM: Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 53, 496-501 (1999).
49. Finelli A, Kaouk JH, Fergany AF, et al.: Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int. 94, 291-294 (2004).
50. Rabets JC, Kaouk J, Fergany A et al.: Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 64, 930-934 (2004).
51. Matin SF, Madsen LT, Wood CG: Laparoscopic cytoreductive nephrectomy: the MD Anderson Cancer Center experience. Urology 68, 528-532 (2006).
52. Pantuck AJ, Zisman A, Dorey F et al.: Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J. Urol. 169, 2076-2083 (2003).
53. Canfield SE, Kamat AM, Sanchez-Ortiz RF et al.: Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical, stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J. Urol. 175, 864-869 (2006).
54. Karakiewicz PI, Trinh QD, Bhojani N et al.: Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indication of disease-specific survival. Eur. Urol. 51(6), 1616-1624 (2006)
55. Margulis V, Brassell SA, Sanchez-Ortiz RF et al.: Resection of retroperitoneal nodal disease in patients with metastatic conventional renal cell carcinoma may improve survival. Cancer 175(3 Pt 1), 864-869 (2008).
56. Patard JJ, Shvarts O, Lam JS et al.: Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J. Urol. 171, 2181-2185; quiz 2435 (2004).
57. Krambeck AE, Leibovich BC, Lohse CM et al.: The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J. Urol. 176, 1990-1995; discussion 1995 (2006).
58. Hutterer GC, Patard JJ, Colombel M et al.: Cytoreductive nophron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer 110, 2428-2433 (2007).
59. Capitanio U, Zini L, Perrotte P et al.: Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology 72, 1090-1095 (2008).
60. Motzer RJ, Rini BI, Bukowski RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006).
61. Bukowski RM, Kabbinavar FF, Figlin RA et al.: Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25, 4536-4541 (2007).
62. Yang JC, Haworth L, Sherry RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
63. Escudier B, Szczylik C, Hutson TE et al.: Randomized Phase II trial of first-line treatment with sorafenib versus interferon α-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280-1289 (2009).
64. Escudier B, Pluzanska A, Koralewski P et al.: Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370, 2103-2111 (2007).
65. Biswas S, Kelly J, Eisen T: Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase, inhibitor era. Oncologist 14, 52-59 (2009).
66. Rosenberg JE, Motzer, RJ, Michaelson MD et al.: Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (inRCC): Updated results of two phase II trials and prognostic factor analysis for survival. Presented at: ASCO Annual Meeting: Chicago, II., USA, 1-5 June. J Clin. Oncol. 25 (2007) (Abstract 5095).
67. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. 163, 343-347 (2000).
68. Feldman AL, Alexander HR Jr, Yang JC et al.: Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer 95, 1637-1643 (2002).
69. Ronnen EA, Kondagunta GV, Ishill N et al.: Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 107, 2617-2621 (2006).